Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Aug 26, 2020; 12(8): 731-751
Published online Aug 26, 2020. doi: 10.4252/wjsc.v12.i8.731
Published online Aug 26, 2020. doi: 10.4252/wjsc.v12.i8.731
Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection
Panagiotis Mallis, Efstathios Michalopoulos, Theofanis Chatzistamatiou, Catherine Stavropoulos-Giokas, Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, Athens 11527, Greece
Author contributions: Mallis P designed and retrieved the data and prepared the whole manuscript; Michalopoulos E and Chatzistamatiou T made critical revisions related to the content of the manuscript; Stavropoulos-Giokas C performed the final approval of the manuscript.
Conflict-of-interest statement: The authors declare no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Panagiotis Mallis, MSc, PhD, Associate Research Scientist, Teaching Assistant, Hellenic Cord Blood Bank, Biomedical Research Foundation Academy of Athens, 4 Soranou Ephessiou Street, Athens 11527, Greece. pmallis@bioacademy.gr
Received: May 15, 2020
Peer-review started: May 15, 2020
First decision: June 3, 2020
Revised: June 10, 2020
Accepted: July 19, 2020
Article in press: July 19, 2020
Published online: August 26, 2020
Processing time: 102 Days and 23.2 Hours
Peer-review started: May 15, 2020
First decision: June 3, 2020
Revised: June 10, 2020
Accepted: July 19, 2020
Article in press: July 19, 2020
Published online: August 26, 2020
Processing time: 102 Days and 23.2 Hours
Core Tip
Core tip: In this review, the therapeutic potential of mesenchymal stromal cells (MSCs) towards coronavirus disease-19 (COVID-19), will be highlighted. Importantly, MSCs exert key immunoregulatory/immunosuppressive properties that can alter significantly the immune responses. Also, MSCs share regenerative abilities, reducing in this way the lung tissue damage. These unique MSCs features, which may significantly improve the overall condition of COVID-19 patients, will be presented in the following article.